Fluoxetine alters the effects of intravenous cocaine in humans

Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse....

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical psychopharmacology Vol. 14; no. 6; p. 396
Main Authors Walsh, S L, Preston, K L, Sullivan, J T, Fromme, R, Bigelow, G E
Format Journal Article
LanguageEnglish
Published United States 01.12.1994
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse. Oral capsules were administered daily containing either placebo (weeks 1 and 4) or fluoxetine in a series of ascending doses (10, 20, 30, and 40 mg) where each dose was given for three to four consecutive days. Cocaine challenge sessions were conducted twice weekly, once at each active dose level and twice during both the placebo and washout phases. Subjects received three ascending intravenous doses of cocaine (0, 20, and 40 mg) 1.5 hours apart and were monitored on physiologic and subjective measures. Cocaine alone increased heart rate, blood pressure, and pupillary diameter and increased subjective reports reflecting positive mood effects and drug liking. Fluoxetine (40 mg) significantly decreased subjective ratings of cocaine's positive mood effects on several visual analog measures. Fluoxetine also attenuated the mydriatic effect of cocaine. No adverse physiologic interactions between the two drugs were observed on cardiovascular measures. These data suggest that fluoxetine may be safely used in the presence of cocaine use and should be investigated further as a potential pharmacotherapy for cocaine abuse.
AbstractList Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse. Oral capsules were administered daily containing either placebo (weeks 1 and 4) or fluoxetine in a series of ascending doses (10, 20, 30, and 40 mg) where each dose was given for three to four consecutive days. Cocaine challenge sessions were conducted twice weekly, once at each active dose level and twice during both the placebo and washout phases. Subjects received three ascending intravenous doses of cocaine (0, 20, and 40 mg) 1.5 hours apart and were monitored on physiologic and subjective measures. Cocaine alone increased heart rate, blood pressure, and pupillary diameter and increased subjective reports reflecting positive mood effects and drug liking. Fluoxetine (40 mg) significantly decreased subjective ratings of cocaine's positive mood effects on several visual analog measures. Fluoxetine also attenuated the mydriatic effect of cocaine. No adverse physiologic interactions between the two drugs were observed on cardiovascular measures. These data suggest that fluoxetine may be safely used in the presence of cocaine use and should be investigated further as a potential pharmacotherapy for cocaine abuse.
Author Sullivan, J T
Fromme, R
Bigelow, G E
Walsh, S L
Preston, K L
Author_xml – sequence: 1
  givenname: S L
  surname: Walsh
  fullname: Walsh, S L
  organization: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224
– sequence: 2
  givenname: K L
  surname: Preston
  fullname: Preston, K L
– sequence: 3
  givenname: J T
  surname: Sullivan
  fullname: Sullivan, J T
– sequence: 4
  givenname: R
  surname: Fromme
  fullname: Fromme, R
– sequence: 5
  givenname: G E
  surname: Bigelow
  fullname: Bigelow, G E
BackLink https://www.ncbi.nlm.nih.gov/pubmed/7884020$$D View this record in MEDLINE/PubMed
BookMark eNotT11LwzAUzcNkbtOfIOQPRJP0tul9EWQ4FQa-6PNI0htWadPRpKL_3g53Xs4H9x44a7aIQyTGuJL3SqJ5kDPAKBAKEZSenThH5YKtpDZKSAN4zdYpfUmpwOhyyZamrkFquWKPu24afii3kbjtMo2J5yNxCoF8TnwIvI15tN8UhylxP3h7vmwjP069jemGXQXbJbq98IZ97p4_tq9i__7ytn3aC18UmEWAylGtLFFj0M26Kr0zWCkKJGuNANoCegOk0WJpnCwIGghqfi8aB3rD7v57T5PrqTmcxra34-_hskP_Ac8uS84
CitedBy_id crossref_primary_10_1016_S0740_5472_99_00076_8
crossref_primary_10_1016_j_pbb_2003_08_013
crossref_primary_10_1016_S0376_8716_02_00104_7
crossref_primary_10_1016_0376_8716_96_01233_1
crossref_primary_10_1523_JNEUROSCI_18_23_10078_1998
crossref_primary_10_1016_S0014_2999_96_00856_4
crossref_primary_10_1016_0376_8716_95_01173_2
crossref_primary_10_1111_j_1471_4159_2006_04163_x
crossref_primary_10_1017_S146114571300059X
crossref_primary_10_1111_j_1521_0391_1998_tb00329_x
crossref_primary_10_1080_10550490490512753
crossref_primary_10_1016_j_psc_2012_03_011
crossref_primary_10_1016_S0091_3057_01_00764_X
crossref_primary_10_1002_hup_1055
crossref_primary_10_1016_0028_3908_95_00166_2
crossref_primary_10_1016_j_bcp_2007_08_003
crossref_primary_10_1016_S0376_8716_98_00032_5
crossref_primary_10_1016_0014_2999_95_00280_X
crossref_primary_10_1016_0376_8716_95_01137_N
crossref_primary_10_1037_1064_1297_11_2_123
crossref_primary_10_1124_jpet_111_186981
crossref_primary_10_1016_j_nic_2007_07_004
crossref_primary_10_1016_j_pnpbp_2013_11_013
crossref_primary_10_1016_S0169_328X_98_00226_5
crossref_primary_10_1016_j_bbr_2014_04_007
crossref_primary_10_1016_S0376_8716_98_00185_9
crossref_primary_10_1021_acs_jctc_2c00002
crossref_primary_10_1177_0269881118805488
crossref_primary_10_1016_S0149_7634_02_00017_9
crossref_primary_10_1111_j_1521_0391_1996_tb00318_x
crossref_primary_10_1016_j_drugalcdep_2006_08_016
crossref_primary_10_1080_00450618_2016_1264479
crossref_primary_10_1016_j_drugalcdep_2014_05_008
crossref_primary_10_1016_j_heliyon_2024_e29979
crossref_primary_10_1111_j_1369_1600_2007_00061_x
crossref_primary_10_1016_j_neuropharm_2013_06_030
crossref_primary_10_1016_S0376_8716_00_00198_8
crossref_primary_10_3109_15563650_2016_1142090
crossref_primary_10_1111_j_1360_0443_2005_00987_x
crossref_primary_10_1016_j_pbb_2003_07_004
crossref_primary_10_1016_S0740_5472_97_00018_4
crossref_primary_10_1016_S0165_1781_98_00048_1
crossref_primary_10_1016_S0091_3057_96_00436_4
crossref_primary_10_1124_pr_114_009514
crossref_primary_10_1016_S0376_8716_98_00164_1
crossref_primary_10_1016_j_pbb_2005_10_013
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/00004714-199412000-00005
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 7884020
Genre Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
.-D
.3C
.GJ
.Z2
01R
0R~
1CY
1J1
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
8L-
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AAQQT
AARTV
AASCR
AASOK
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABIVO
ABJNI
ABVCZ
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFDTB
AFFNX
AFUWQ
AGINI
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJIOK
AJNWD
AJNYG
AJZMW
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BOYCO
BQLVK
BS7
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
H0~
HLJTE
HZ~
H~9
IKREB
IKYAY
IN~
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
N4W
N9A
NEJ
NPM
N~7
N~B
N~M
O9-
OAG
OAH
OCUKA
ODA
OJAPA
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OMH
OPC
OPUJH
OPX
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
YOC
ZFV
ZGI
ZXP
ZY1
ZZMQN
ID FETCH-LOGICAL-c339t-f46be81aeed79b6be65cb7961efe0829442a49c74e29a957b03e4d4f1c333db42
ISSN 0271-0749
IngestDate Sat Sep 28 07:32:35 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c339t-f46be81aeed79b6be65cb7961efe0829442a49c74e29a957b03e4d4f1c333db42
PMID 7884020
ParticipantIDs pubmed_primary_7884020
PublicationCentury 1900
PublicationDate 1994-12-01
PublicationDateYYYYMMDD 1994-12-01
PublicationDate_xml – month: 12
  year: 1994
  text: 1994-12-01
  day: 01
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical psychopharmacology
PublicationTitleAlternate J Clin Psychopharmacol
PublicationYear 1994
SSID ssj0014725
Score 1.786988
Snippet Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study...
SourceID pubmed
SourceType Index Database
StartPage 396
SubjectTerms Adult
Affect - drug effects
Arousal - drug effects
Blood Pressure - drug effects
Cocaine - antagonists & inhibitors
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Fluoxetine - adverse effects
Fluoxetine - therapeutic use
Heart Rate - drug effects
Humans
Male
Substance Abuse, Intravenous - rehabilitation
Substance-Related Disorders - rehabilitation
Title Fluoxetine alters the effects of intravenous cocaine in humans
URI https://www.ncbi.nlm.nih.gov/pubmed/7884020
Volume 14
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEF48EHwRT7zZB_HFRtzN5noRRCylYhGt0DfJJrMgaFtsFfXXO3vYjbXi8RLCLglJvo_J7Ox8M4TssVzkKpVRwJgqAgFRGaQlqABYBEzFWai4FidftOLGjWh2oo7f0TXqkqE8LN4m6kr-gyqOIa5aJfsHZEc3xQE8R3zxiAjj8VcY1--fei9aswwHZtd7MJ6icadDt8-2DCtavvzO1ggxjfkG3_ilI62kFWj1fW3ravR9YMIx1wej2LHO5XCp-Od-tLrX1PQJ2fXH3oNtz37lww6mfrBP4bDWiScsQP8j-2RKRYUyVbsY2ra1X-y1rQNsFioJEzrrRbAPsbuRYw8rMPYfDI64aNeL3h8nx-pou5lpMp2k2hS2dFjHbTeJxHTnHb2TS_n6qO456dnmyZy749iCxDgm7UWy4JCjJ5YeS2QKustk_9LC9lqjba-wG9ToPr2sALpCjj2HqOUQRQ5RxyHaU7TCIeo4hGPUcmiV3NTP2qeNwPXUCIowzIaBErGElOXoGiWZxPM4KmSSxQwUaJm1EDwXWZEI4FmeRYk8CkGUQjG8PCyl4GtkptvrwjqhKUiuYsBfgEQXh6s8PAI0CawUIWc5hw2yZr_Lbd8WTrl1H2zzu4ktMu-ptk1mFbIZdtDpG8pdA9g7QRdT3A
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fluoxetine+alters+the+effects+of+intravenous+cocaine+in+humans&rft.jtitle=Journal+of+clinical+psychopharmacology&rft.au=Walsh%2C+S+L&rft.au=Preston%2C+K+L&rft.au=Sullivan%2C+J+T&rft.au=Fromme%2C+R&rft.date=1994-12-01&rft.issn=0271-0749&rft.volume=14&rft.issue=6&rft.spage=396&rft_id=info:doi/10.1097%2F00004714-199412000-00005&rft_id=info%3Apmid%2F7884020&rft_id=info%3Apmid%2F7884020&rft.externalDocID=7884020
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0271-0749&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0271-0749&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0271-0749&client=summon